Inclusion Criteria:~1. ≥55 and ≤85 years of age~2. Patient who was diagnosed mild to moderate Alzheimer's
disease by National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and
Related Disorders Association(NINCDS-ADRDA) or National Institute on Aging-Alzheimer's Association(NIAAA)~3.
Korean Mini-Mental State Examination(K-MMSE) score 15 to 26~4. Patient who maintained on donepezil without dose
escalation or reduction for at least during 3 months before screening (visit 1)~5. Clinical Dementia
Rating(CDR) score 0.5 to 2.0 at screening (visit 1)~6. Written informed consent voluntarily~7. Patient who has
a relative/caregiver who support the information of patient's status~8. Patient who are deemed adequate to
participate in the clinical trial by the investigator~9. Infertility or patients and his/her spouse consent
with contraception during the study period~
